Abstract Library

#4597 FIT-NETs: Assessing the effects of an exercise programme on the physical and emotional well-being of patients with advanced G1-2 NETs of GEP or unknown origin

Introduction: Physical activity programs in solid tumours have shown to improve symptom control and even survival, but their impact on NENs remains unexplored. Advanced disease, systemic therapy, and hormonal secretion in these tumours often lead to muscle wasting and sarcopenia.

Conference:

Presenting Author: Anton-Pascual B

Authors: Anton-Pascual B, Rodriguez-Gomez J, de Cima A, Herrero-Llorente A, Modrego A,

Keywords: FIT-NET, physical exercise program, Quadriceps, MEP & MIP, QoL,

#4498 Quality of life outcome after each cycle in NET patients receiving peptide receptor radionuclide therapy (PRRT)

Introduction: Quality of Life (QoL) Questionnaire GI NET21 was developed specifically for neuroendocrine tumours (NET). A significant proportion of all patients with GEP-NETs will ultimately present with a wide variety of NET-related symptoms such as skin flushing, diarrhoea and pain as well as disease related worries that can reduce QoL. Peptide receptor radionuclide therapy (PRRT) is an established treatment in NETs and has been shown to extend survival. However, QoL data post PRRT is still somewhat limited.

Conference:

Presenting Author: Vito I

Authors: Vito I, Santillan N, Davis N, Navalkissoor S,

Keywords: Lu-177-DOTATATE, PRRT, Quality of Life,

#3732 Urine 5-HIAA levels and quality-of-life in neuroendocrine neoplasia – Is there an association?

Introduction: Patients with neuroendocrine neoplasia (NEN) experience psychological distress related to secreting tumors. 5-hydroxyindoleacetic acid (5-HIAA) is a metabolite of serotonin, an important secretory product in carcinoid syndrome.

Conference:

Presenting Author:

Authors: Chaudhry R, White B, Chandrakumaran K, Vincent R, Srirajaskanthan R,

Keywords: neuroendocrine neoplasm, biomarker, 5-HIAA, Health-related quality of life (HRQL),

#3578 Optimal PLAnning of treatment and research of Neuroendocrine Tumors (NETs) in Australia: The PLANET registry and patient reported outcomes via PLANET App

Introduction: Neuroendocrine Neoplasms (NENs) are challenging to diagnose and manage due to their varied behaviour. Despite usually having an indolent course, they are often metastatic at diagnosis and can be associated with significant long-term morbidity and impaired quality-of-life (QOL). The PLANET registry was established to collate clinical data from tertiary NET centres and integrate these with real-time patient reported outcomes (PROs) enabled by the smartphone-based PLANET App.

Conference:

Presenting Author: Leyden S

Authors: Leyden S, Cummins M, Pavlakis N, Ransom D, Price T,

Keywords: data, PROMS, PROs, QOLs, real-world data,

#3460 Lanreotide 120 mg every 28 days (LAN) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (panNET) in routine clinical practice in Iberia

Introduction: Clinical trial data show prolonged progression-free survival (PFS) with LAN in metastatic enteropancreatic NET; real-world data may demonstrate effectiveness in routine care.

Conference:

Presenting Author: Alonso T

Authors: Alonso-Gordoa T, Capdevila J, González E, Teulé A, Anido U,

Keywords: net, pancreas, lanreotide, clinical practice,